Forte Biosciences, Inc.
FBRX
$12.65
-$1.01-7.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -118.81% | 14.74% | 32.92% | -68.61% | -26.36% |
| Total Depreciation and Amortization | 30.00% | 0.00% | 0.00% | 11.11% | 50.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 155.08% | -32.38% | 0.38% | -0.25% | 1.40% |
| Change in Net Operating Assets | 214.77% | -517.97% | -109.55% | 10,587.27% | 98.59% |
| Cash from Operations | -3.46% | -23.07% | -37.01% | 10.96% | 25.67% |
| Capital Expenditure | -96.77% | -- | -- | 100.00% | 64.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 201.10% | -- | -- | -- | -- |
| Cash from Investing | 200.84% | -- | -- | 100.00% | 62.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.98% | 883,233.33% | -- | -100.00% | -96.17% |
| Repurchase of Common Stock | -650.00% | 71.43% | 30.00% | 37.50% | -33.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -106.60% | -112,000.00% | -- | -- | -- |
| Cash from Financing | -104.48% | 2,593,950.00% | 80.00% | -25.00% | 89.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 301.50% | 172.29% | -36.81% | 11.00% | 26.26% |